←Back to Expert Scholars
Translational Medicine / 转化医学Pembrolizumab MSI-H First Reports
Dung T. Le
MD
🏢Johns Hopkins University🌐USA
Professor of Oncology
75
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Dung Le co-led the first trial demonstrating that pembrolizumab produces durable responses in MSI-H colorectal and non-colorectal cancers, establishing the MSI-H immunotherapy paradigm. Her work defined neoantigen burden as the key mechanism behind MSI-H IO sensitivity.
Share:
🧪Research Fields 研究领域
MSI-H pembrolizumab
KEYNOTE-164
neoantigen burden MSI
colorectal immunotherapy
biomarker MSI
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Dung T. Le 的研究动态
Follow Dung T. Le's research updates
留下邮箱，当我们发布与 Dung T. Le（Johns Hopkins University）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment